103 related articles for article (PubMed ID: 3261273)
1. Interleukin 2 increases protection against experimental rabies.
Perrin P; Joffret ML; Leclerc C; Oth D; Sureau P; Thibodeau L
Immunobiology; 1988 May; 177(2):199-209. PubMed ID: 3261273
[TBL] [Abstract][Full Text] [Related]
2. Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies.
Wu X; Franka R; Henderson H; Rupprecht CE
Vaccine; 2011 Jun; 29(25):4195-201. PubMed ID: 21514343
[TBL] [Abstract][Full Text] [Related]
3. A potency test which simulates natural exposure for measuring post-exposure activity of rabies vaccines. A proposal for preparing a relevant international reference preparation.
Bijlenga G
Dev Biol Stand; 1978; 40():203-8. PubMed ID: 567153
[TBL] [Abstract][Full Text] [Related]
4. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
Lodmell DL; Esposito JJ; Ewalt LC
Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
[TBL] [Abstract][Full Text] [Related]
5. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines.
Franka R; Wu X; Jackson FR; Velasco-Villa A; Palmer DP; Henderson H; Hayat W; Green DB; Blanton JD; Greenberg L; Rupprecht CE
Vaccine; 2009 Nov; 27(51):7149-55. PubMed ID: 19925945
[TBL] [Abstract][Full Text] [Related]
6. Appraisal of rabies vaccine potency by determination of in vitro, specific interleukin-2 production.
Joffret ML; Zanetti C; Morgeaux S; Leclerc C; Sureau P; Perrin P
Biologicals; 1991 Apr; 19(2):113-23. PubMed ID: 1888490
[TBL] [Abstract][Full Text] [Related]
7. Pre-immunization and post-exposure treatment with inactivated rabies vaccine of chick embryo cell culture origin (CEC).
Kondo A
Dev Biol Stand; 1978; 40():147-53. PubMed ID: 98373
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 production in vitro: a new approach to the study of rabies vaccine immunogenicity as appraised by testing different glycoprotein presentations.
Perrin P; Joffret ML; Oth D; Leclerc C; Sureau P; Thibodeau L
Vaccine; 1988 Aug; 6(4):331-8. PubMed ID: 2461004
[TBL] [Abstract][Full Text] [Related]
9. In vitro potency tests: challenges encountered during method development.
Yomayuza CL; Thiel HJ; König M
Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600
[TBL] [Abstract][Full Text] [Related]
10. [Kinetics of the reactions to experimental infection in mice after or without vaccination against rabies: study of etio-pathogenesis (author's transl)].
Blancou J; Andral B; Andral L
Ann Microbiol (Paris); 1979; 130B(4):485-92. PubMed ID: 539695
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cytokines concentration and percentage of survival of rabies virus-infected mice submitted to anti-rabies Vero-cell propagated vaccine and P. acnes.
Megid J; Appolinario CM; Mazzini AM; Almeida MF
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):192-6. PubMed ID: 16930720
[TBL] [Abstract][Full Text] [Related]
12. Production, purification and analysis of an experimental DNA vaccine against rabies.
Diogo MM; Ribeiro SC; Queiroz JA; Monteiro GA; Tordo N; Perrin P; Prazeres DM
J Gene Med; 2001; 3(6):577-84. PubMed ID: 11778904
[TBL] [Abstract][Full Text] [Related]
13. Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies.
Perrin P; Thibodeau L; Sureau P
Vaccine; 1985 Sep; 3(3):325-32. PubMed ID: 4060842
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
Nunberg JH; Doyle MV; York SM; York CJ
Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4240-3. PubMed ID: 2786210
[TBL] [Abstract][Full Text] [Related]
15. Ineffectiveness of rabies vaccination alone for post-exposure protection against rabies infection in animal models.
Zhang Y; Zhang S; Li L; Hu R; Lin H; Liu H; Liu F; Shao H; Liu Y
Antiviral Res; 2016 Nov; 135():56-61. PubMed ID: 27737787
[TBL] [Abstract][Full Text] [Related]
16. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2.
Patial S; Chaturvedi VK; Rai A; Saini M; Chandra R; Saini Y; Gupta PK
Vaccine; 2007 May; 25(20):4020-8. PubMed ID: 17391817
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an animal rabies vaccine by use of two types of potency tests.
Baer GM
Am J Vet Res; 1997 Aug; 58(8):837-40. PubMed ID: 9256966
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a live canine adenovirus-vectored rabies virus vaccine in swine.
Liu Y; Zhang S; Ma G; Zhang F; Hu R
Vaccine; 2008 Oct; 26(42):5368-72. PubMed ID: 18721839
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin.
Wiktor TJ
Dev Biol Stand; 1978; 40():255-64. PubMed ID: 680397
[TBL] [Abstract][Full Text] [Related]
20. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees.
Perrin P; Joffret ML; Zanetti C; Bourhy H; Gontier C; Fritzell C; Leclerc C; Sureau P
Vaccine; 1991 Aug; 9(8):549-58. PubMed ID: 1771968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
